Podcasts about Lung cancer

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive modeling for recurrence and drug resistance, and personalized treatment strategies. Dr. Marignani is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University in Halifax, Novia Scotia, and she spoke about this topic at the 2025 World Conference on Lung Cancer.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.

Dr. Halmos from Montefiore in New York shares his views on the most impactful practice changing or informing data for lung cancer from the ASCO 2025 meeting.

After experiencing a persistent cough and a pain in his side, Keith Jay of Texas was encouraged to seek medical advice. Although it took a few months, in November of 2024 he was diagnosed with stage 4 lung cancer that had metastasized to his lymph glands, bones and spine. Refusing chemotherapy, a friend encouraged him to contact Corrie Yelland who told him about cannabis oil. Nine months later he is cancer free. A truly inspirational story. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

In this JCO Article Insights episode, Dr. Joseph Matthew interviews authors Dr. Yang Zhang and Dr. Haiquan Chen about their recently published JCO article, "Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma" TRANSCRIPT Joseph Mathew: Welcome to the Journal of Clinical Oncology Article Insights episode for the August issue of the JCO. This is Joseph Mathew, editorial fellow for JCO, and today, it is my pleasure to have with us Dr. Haiquan Chen and Dr. Yang Zhang, authors of the recently published manuscript, "Phase 3 Study of Mediastinal Lymph Node Dissection for Ground-Glass Opacity-Dominant Lung Adenocarcinoma," which we will be discussing today. Dr. Chen is the Director of the Institute of Thoracic Oncology at Fudan University and the Chief of Thoracic Surgery at Fudan University Shanghai Cancer Center, where he is also the Head of Thoracic Oncology MDT and the Director of the Lung Cancer Center. Dr. Chen is a surgeon-scientist and a pioneer in developing individualized surgical strategies for early-stage non-small cell lung cancer. Dr. Zhang is a surgical oncologist and a member of the team which Dr. Chen leads at the Fudan University Shanghai Cancer Center. Welcome Dr. Chen and Dr. Zhang. Thank you very much for accepting our invitation and joining us today as part of this podcast episode. To summarize the salient points, this study presented the interim analysis of a multi-center, open-label, non-inferiority, randomized controlled trial investigating the necessity of systematic mediastinal lymph node dissection at the time of segmentectomy or lobectomy in patients with clinical stage T1N0M0 ground-glass opacity-dominant invasive lung adenocarcinoma, as defined by a consolidation-to-tumor ratio of 0.5 or less on thin-section computed tomography and a maximum tumor diameter of 3 cm or less. Eligible participants with intraoperatively confirmed invasive adenocarcinoma on frozen section analysis were randomized to either the systematic mediastinal lymph node dissection arm or to no mediastinal lymph node dissection. In the latter experimental group, mediastinal lymph nodes comprising the N2 nodal stations were not dissected, and the hilar nodes were variably addressed at the discretion of the operating surgeon. The primary endpoint of the trial was disease-free survival at 3 years. Secondary endpoints included perioperative outcomes, the status of lymph node metastasis in the systemic lymph node dissection arm, and 3-year overall survival. Before the trial reached its accrual target, a pre-planned interim safety analysis set for the time point when enrollment reached 300 patients was performed. It was noted that while none of the patients in either arm had nodal metastasis on postoperative pathological evaluation, lymph node dissection-related intraoperative and postoperative complications were more commonly observed in the systematic lymph node dissection arm, including one life-threatening episode of massive bleeding. Since this met the predefined criteria for trial termination, and in accordance with the principle of non-maleficence, further recruitment was stopped and the trial terminated. Although the 3-year disease-free survival and the overall survival for the enrolled patients were comparable, operative outcomes, including the duration of surgery, blood loss, chest tube duration, length of postoperative stay, and the rate of clinically significant complications, were significantly lower in the experimental arm compared with the systematic lymph node dissection group. The authors concluded that for well-selected patients, mediastinal nodal dissection could be omitted without adversely affecting oncological outcomes, representing a significant shift in current surgical practice, given that guidelines the world over recommend systematic lymph node dissection or sampling for all invasive lung cancers. In summary, this study addressed a clinically relevant question with regard to the extent of nodal dissection, especially in the light of recent evidence recommending less extensive parenchymal dissections for early-stage non-small cell lung cancer, with the findings suggesting that invasive lung adenocarcinoma associated with ground-glass opacities of consolidation-to-tumor ratio up to 0.5 was an excellent predictor of tumor biology, and in clinical T1N0M0 lesions, a reliable predictor of negative mediastinal lymph node involvement. So Dr. Chen and Dr. Zhang, could you tell us some more about what led you to do this research and the challenges which you faced while recruiting patients for this trial? Dr. Yang Zhang: Dr. Mathew, thank you for your summary. The current clinical guidelines recommend systematic lymph node dissection or sampling for every patient with early-stage lung cancer, regardless of their lymph node status. And in our clinical practice, we observe that this procedure causes a lot of surgical complications including chylothorax and recurrent laryngeal nerve injury. Furthermore, dissecting the tumor-draining lymph nodes actually may potentially damage the body's anti-tumor immunity. So, Dr. Chen proposed the concept of selective lymph node dissection, which we aimed to dissect the metastatic lymph nodes, while at the same time we try to preserve as many uninvolved lymph nodes as possible. So previously, we have conducted a series of retrospective studies to identify reliable predictors of nodal negative status in certain mediastinal zones, and we have performed a prospective observational phase 2 clinical trial to validate that the six criteria we proposed are 100% in predicting node-negative status. And this forms the basis for our phase 3 clinical trial. Dr. Haiquan Chen: This trial is only one of the series of trials. The meaning of this trial you already said. And for a long time, from the surgeon's point of view, we considered minimally invasive surgery. It minimizes the size of the incision and minimizes the number of the holes we made. So, the true and the high-impact of minimally invasive, we make a concept of minimal dissection, that means organ-level minimally invasive. So we proposed the concept of minimally invasive 3.0, that means minimal incision, minimal dissection (that means organ-level minimal), and systemic minimally invasive. So at first, we judged from the point of minimally invasive surgery. As long as immunotherapy is widely used in the clinical practice, we know immunotherapy, that means you use drugs to stimulate and activate the lymph node site. If we dissect all the metastatic lymph nodes, cut them out, how can we restimulate that lymph node site? So, from minimally invasive trauma and second, from the functional aspect, to try to save as many uninvolved lymph nodes as possible. Joseph Mathew: Thank you, Dr. Chen. That's a very interesting concept that you alluded to even in the discussion of this paper, as to the potential role of the non-metastatic lymph nodes as immune reservoirs. So, coming back to this paper, were there any challenges which you faced while recruiting patients for this trial? Dr. Haiquan Chen: The criteria is very clear. That means invasive adenocarcinoma, that means most of the centimeter is 3.0 centimeter and also CTR ratio less than 0.5. And we can see that, you know, we did study about that. Even the invasive component of the subsolid nodule, it's bigger than the solid part. That means even the pure GGO, we can find out that there's still some invasive component. From this point of view, pure GGO and subsolid GGO, from this part of invasive carcinoma, that means it's a special clinical subtype that we, from retrospective study and also prospective study, we find out this group of patients, there are no mediastinal lymph node metastasis. So I think it's very important for this kind of group that we can avoid doing the mediastinal lymph node dissection. And we can do organ-level minimally invasive surgery. And also, we try to keep the patient's immune function as normal as possible. Dr. Yang Zhang: Well, Dr. Mathew, we believe that the biggest challenge when we are enrolling these patients is that there needs to be a paradigm shift in the mind because systematic lymph node dissection has long been the standard of care. And some patients may misunderstand. Before the enrollment, we have to give them informed consent, but if the patient hears that they may be enrolled in the no-lymph-node-dissection group, they may feel that they do not receive radical, curative-intent surgery. So we believe, as Dr. Chen has said, after the release of our results, the no-lymph-node dissection may be incorporated in the future guideline for those patients without lymph node involvement, we can just omit the lymph node dissection. Joseph Mathew: The study described two pre-planned interim points during the course of subject enrollment when the data was analyzed. So Dr. Chen and Dr. Zhang, could you please explain a little more about these two interim points of analysis that were planned and the rationale behind it? Dr. Yang Zhang: When conducting this trial, we have two concerns. One is if there is any lymph node metastasis, there may be omission of metastatic lymph nodes not dissected in the no-lymph-node-dissection group. And there is another concern is that if all these lymph nodes are uninvolved, then dissecting these lymph nodes may cause life-threatening complications. So, we set the 150 interim analysis to ensure that there is no lymph node involvement in this group. And the other early termination criteria is set because if there is no lymph node involvement found in both groups, then a severe complication which is life-threatening is unacceptable because it threatens the patient's safety. Joseph Mathew: So, although you did briefly allude to in the paper, what was the basis for selecting DFS as the primary endpoint when the objective of this trial was to assess nodal involvement in this subset of tumors? Dr. Yang Zhang: Well, previously, we have done a series of retrospective studies and one prospective phase 2 trial. And in these studies, we have identified that GGO-dominant lung adenocarcinoma, even if it's invasive, it has no lymph node involvement. So this phase 3 trial was primarily designed to compare the survival outcomes. But as the trial went on, as Dr. Chen has concerns that if the patients have no lymph node metastasis at all, it may be unfair to dissect the lymph nodes for patients enrolled in the systematic lymph node dissection group. So there is one life-threatening complication that happens due to dissecting the lymph nodes and injury to the superior vena cava, which leads to massive bleeding. It is at this point that we decided to terminate this trial for patient safety concerns. Joseph Mathew: Yeah, that's a very fair point. So you made sure that the ethical considerations were kept intact. So another point was, there was a mention in the study of the historical data from your institution suggesting a 3-year disease-free survival of 96.6% for patients with clinical T1N0M0 ground-glass opacity-dominant invasive lung adenocarcinoma. So could you please elaborate on the patterns of recurrence which you noted for this group of patients who had developed a recurrence? Dr. Haiquan Chen: Yeah, I think over 90% 3-year DFS, that's the least. From our retrospective data for this kind of group of patients, their DFS is so good. To the best of my knowledge, almost 100%. So this is very conservative, 94, 90% is very conservative. I think the trial eventually would have been positive. It's a special clinical subtype, even for invasive adenocarcinoma, their prognosis is much better than the other type of invasive adenocarcinoma. Joseph Mathew: So this question may be slightly outside the purview of this study, but in your clinical practice, would you advocate either segmentectomy or lobectomy for all patients meeting the trial criteria, that is, lesions measuring 3 cm or less with a CTR of up to 0.5? Or is there a subgroup of patients you would recommend a wedge dissection for? Dr. Haiquan Chen: I think CTR ratio is one parameter and also the location is another very important parameter. So we put it together to make a decision, the patient should do a lobectomy or segmentectomy. Even for an ongoing trial, for even the patient, invasive adenocarcinoma, we can do in the right location, even wedge, it can achieve enough negative margin in the ongoing trial to verify the comparable result for the patient, we can do the wedge dissection. So not just the CTR ratio, that's not the only parameter to make a decision on what kind of procedure we'll do. Joseph Mathew: Yeah, great point, Dr. Chen. So from my perspective, this study was a well-designed, randomized control trial based on a relevant and clinically valid research question. So what, in your opinion, are the main strong points of this study? Dr. Yang Zhang: We believe that this study represents the first randomized clinical trial published, yet, regarding the topic of selective lymph node dissection. It basically offers the highest level of evidence. We believe our results should be incorporated in the future clinical guideline. Joseph Mathew: Given the increasing incidence of these lesions, I think it was- a randomized control trial in this arena was much awaited. And the other point is that GGO-dominant lung adenocarcinomas, the specific clinical guidelines are not very clear. So I think your study brought out that lymph node dissection for these tumors which satisfy the eligibility criteria could be omitted safely. Important consideration here is that the conclusions of the trial were based on an interim analysis, and this analysis was not planned for an early assessment of the primary endpoint. In other words, the study was not adequately powered to detect a significant difference in DFS at 3 years. So Dr. Chen and Dr. Zhang, what do you perceive are the most important limitations of this study which you feel should be addressed in future research? Dr. Haiquan Chen: So the surgery now is more individualized. I think the surgery from the last two decades, from the maximum tolerable intervention to minimum effective treatment, there's a big shift. So I think that the consensus, we can preserve normal lung parenchyma as much as possible. For the lymph nodes, I think that the big shift, we should shift it to keep as many as uninvolved lymph nodes as possible. So that's very important, not just to reduce the intraoperative trauma, but also to keep the immune environment as normal as possible. Joseph Mathew: Another point was the limited long-term follow-up data to determine the actual impact of omitting lymph node dissection on local-regional disease control. So is any future follow-up planned to assess the long-term survival outcomes for the 302 patients which were enrolled in this trial? Dr. Haiquan Chen: Yeah, I think that's very important for us. This trial we terminated just because if we keep the trial going, it's unfair for the mediastinal lymph node dissection group. We tried to just stop here, and we shifted to the single-arm trial. So, 2 or 3 years, this trial and another trial, they will give our final result to demonstrate more if selective mediastinal lymph nodes have a better result than ever before. And we will support the mediastinal lymph node dissection. That's one way. And the American College just asked me, how can we put this policy into clinical practice in the United States? Because most of the patients they meet have solid tumors. So we have another trial, try to figure out how we can make sure before and intraoperative the lymph node status is negative or positive, and then we can solve that problem and put this policy into clinical practice in the Western society. Joseph Mathew: Great. So that would be something we should all be looking forward to. So, this brings me to the final point of discussion on future research in this field. Dr. Chen, you commented in the paper that future studies should focus on improving the reproducibility of CTR evaluation. What are your thoughts on this subject? Dr. Haiquan Chen: The CTR ratio, the concept from the JCOG 0201, just a concept from that prospective study, the phase 2 study, only subgroup analysis they give the concept of CTR ratio and the diameter. How can we reproduce? In our group and also I believe in Japan and in China, in Korea, and in our daily practice, I think CTR ratio is not a big issue. There are two very important things. One, you make sure the CTR ratio, not in a common CAT scan, but in a high-resolution CAT scan. So the imaging, that's the first thing. And the second, not from the single section and a two or three section, you make sure that your calculation is accurate. That's not just the single section, you make sure that you got the conclusion, the CTR ratio is the same number. We make sure that totally we, from the top to the bottom of the whole lesion, we make sure that the CTR ratio is accurate. Joseph Mathew: Thank you, Dr. Chen. I think that would involve training our radiologists also to be aware of the CTR ratio and how it should be interpreted. So another very interesting concept which you had alluded to in the discussion was the potential role of non-metastatic lymph nodes as immune reservoirs. So how do you think we could preserve these nodes and do you think sentinel node biopsies would play a role in future? Dr. Yang Zhang: Actually, Dr. Chen has also led some basic research on this topic. We are investigating the immunological role of the tumor-draining lymph nodes. And our preliminary results have already shown that the tumor-draining lymph nodes of lung cancer, especially those uninvolved lymph nodes, have a vital role in the anti-tumor immunity and also effective response to the current anti-PD-1 immunotherapy. In the future, we believe that by incorporating our clinical evidence and those findings from our basic research, we will be able to provide very strong rationale to support selective lymph node dissection. Joseph Mathew: So lastly, what are the questions that still remain to be answered and what do you perceive as the next step in this field? Dr. Haiquan Chen: I think for the lung cancer surgery, especially for the cT1N0M0, they are more individualized. We can, based on the patient, the location, the CTR ratio, we can do wedge dissection, or segmentectomy, or lobectomy. For the lymph node dissection, we can do no mediastinal lymph node dissection or selective, only to dissect the positive one, or we have to do the systemic mediastinal lymph node dissection. So we can see there are too many combinations. So in the near future, for the surgery perspective, we have it more individualized. In the future, we just try to make sure we do not cut as many as possible. We just make sure that we can avoid over-diagnosis or overtreatment or over-dissected. I think that in the near future, that goal will come true. Joseph Mathew: That's a great point, Dr. Chen. So that would be something also for the thoracic oncology community to work towards. This wraps up today's episode of JCO Article Insights. Dr. Chen and Dr. Zhang, thank you very much for taking the time to join us today in what has been a very insightful session. Dr. Haiquan Chen: Thank you. Dr. Yang Zhang: Thanks. Joseph Mathew: To our audience, thank you for listening. Please stay tuned for more interviews and articles, summaries, and be sure to leave us your comments and ratings. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In this episode, Dr. Paul Wheatley-Price chats with Dr. Adrian Sacher on everything there is to know about KRAS lung cancer. What is KRAS lung cancer, how is it tested, and what it means in terms of treatment options for those who have this subtype of lung cancer. Dr. Adrian Sacher is a Thoracic Medical Oncologist at the Princess Margaret Cancer Centre and Assistant Professor in the Departments of Medicine & Immunology at the University of Toronto.

An update on natural thyroid availability and the FDAA correction on disseminated sarcoidosis and stressI'm a former smoker. Should I be concerned about beta carotene in the Alpha Base multivitamin?A comment from a user of lithium orotate for the last eleven yearsDoes long-term use of Horse Chestnut cause a thiamin deficiency?

Thursday, July 10th, Jeffrey Mosher was on the road to UM Health-Sparrow Lansing, 1215 E. Michigan Ave., Lansing, Michigan. The celebration was regarding University of Michigan Health-Sparrow just completing its 500th ION robotic bronchoscopy, an innovative procedure that allows clinicians to maneuver a robotic-assisted catheter into the lungs to target hard-to-reach nodules. It means we're able to reach small or remote nodules that may contain the first signs of lung cancer and then address the cancer before it spreads. UM Health-Sparrow was the first hospital in the region to use ION and we're ready to celebrate our 500th milestone. A patient whose cancer was detected at an early stage will be available to discuss how ION changed his life, plus physicians will talk about the impact of the procedure. For this video, you see the room with procedures, interviews with Dr. Mohanad M. Saleh, MD Pulmonary Disease, Critical Care Medicine, Interventional Pulmonology and then patient Dan, an example of one of the 500 treated at UM Health-Sparrow with the ION robotic bronchoscopy process. Other footage from the conference room celebration of the 500 process milestone. » Visit MBN website: www.michiganbusinessnetwork.com/ » Watch MBN's YouTube: www.youtube.com/@MichiganbusinessnetworkMBN » Like MBN: www.facebook.com/mibiznetwork » Follow MBN: twitter.com/MIBizNetwork/ » MBN Instagram: www.instagram.com/mibiznetwork/

Thriving 10 Years After Lung Cancer Dr. Madeleine Long Shares Her Story with Dr. Michael Klaper by Chef AJ

Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC

Shirley Quach, registered respiratory therapist and Director of Person-Centered Care & Programs at the Lung Health Foundation

In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Key Topics: •⁠  ⁠Overview of Dato-DXd and its FDA approval •⁠  ⁠Mechanism of action and study design of the TROPION Lung trials •⁠  ⁠Efficacy and safety profile of Dato-DXd •⁠  ⁠Management of side effects and clinical pearls •⁠  ⁠Treatment sequencing for EGFR-mutated NSCLC Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations.  Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD). We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice. Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!

LCC in Cantonese: Novel Treatment for Advanced EGFR Mutant Lung Cancer by IASLC

Lung Cancer Update The Treatment Path I've Chosen with Dr. Matthew Lederman by Chef AJ

Lung cancer, particularly non-small cell lung cancer (NSCLC), is the deadliest cancer worldwide. Cigarette smoking is one of the main causes, but not every smoker develops the disease. This suggests that other biological factors help determine who develops cancer. Researchers from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis, and from the Richard L. Roudebush Veterans Affairs Medical Center have now found that cigarette smoke, combined with a weakened DNA repair system, can trigger the early stages of lung cancer, particularly NSCLC. This work, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, was recently published in Volume 16 of Oncotarget. Full blog - https://www.oncotarget.org/2025/08/11/cigarette-smoke-and-weak-dna-repair-a-double-hit-behind-lung-cancer-risk/ Paper DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Video short - https://www.youtube.com/watch?v=UEiCz834a8c Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

AITA: For telling my friend to stop turning her hobbies into side hustles? DIRT ALERT: Brooke Hogan shares why she didn't go to Hulk Hogans funeral, we talk A Breath of Hope Lung Cancer Walk & Run, and intergenerational summer camp See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lung cancer remains one of the deadliest cancers in the United States, in part because it’s often detected too late. On The Spark, UPMC Thoracic Surgeon Dr. Troy Moritz joined the show to shed light on who should be screened, what symptoms not to ignore, and how technology is changing the way lung cancer is detected and treated. Who Should Be Screened? Dr. Moritz emphasized the importance of lung cancer screenings for a specific group:“We’re looking for people that are age 50 to up to 80 years of age and those people that have smoked what we consider to be 20 pack years,” he explained.That includes anyone who smoked a pack a day for 20 years — or an equivalent amount — and hasn’t quit within the last 15 years. These high-risk individuals are encouraged to undergo low-dose CT scans, which Dr. Moritz described as simple and noninvasive.“It’s pretty much just get in the CAT scan machine and buzz in, buzz out,” he said. “It’s not an MRI, so you don’t have to worry about that claustrophobic feeling.”Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

RaeAnn Tucker from the Henry and Stark County Health Departments and First Choice Healthcare Clinics joined Wake Up Tri-Counties to talk about National Breastfeeding Awareness Week, Radon Testing for Lung Cancer Day, swimming safety, CPR classes, and insurance navigators in Galva and Geneseo. August marks Breastfeeding Awareness Month, and the Henry and Stark County Health Departments—together with First Choice Healthcare—highlight programs supporting local families. WIC agencies and peer counselors stress breastfeeding's health, nutritional, and environmental benefits, offering guidance at 309-852-5272 and online. With World Lung Cancer Day on August 1, officials urge residents to test homes for radon, a leading cancer risk; radon kits are available at health department offices. Meanwhile, summer safety reminders emphasize swimming supervision and CPR skills, with certification classes offered monthly. Health insurance navigators will assist residents at multiple county events, and back-to-school physicals are available by appointment at local clinics.

LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania by IASLC

In this episode of the Southern Medicine Podcast, Loretta Loftus, MD, MBA, Vice Chair, Department of Breast Oncology at Moffitt Cancer Center, speaks with Lary Robinson, MD, a thoracic surgeon at Moffitt Cancer Center. Dr. Robinson reflects on his path to thoracic surgery, how the field has evolved, and key advances in lung cancer treatment—including the promise of immunotherapy and the importance of early screening. The conversation also touches on multidisciplinary care, as well as advice for primary care providers.

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Francis Spruit, born in Djakarta, Indonesia, June 1959 The Netherlands - USA dual citizen Married to my high school sweetheart Roslyn Four kids and seven grand kids! Technology Program Manager, a mere two months away from retirement. Diagnosed December 2007 with Non Small Cell Lung Cancer, Stage 1B Treatment: right upper lobectomy on Christmas Eve 2007. Four cycles of Cisplatin and Etoposide chemotherapy in the spring of 2008. No active treatment since then. Annual chest CT scans to ‘keep an eye on things'. Actively advocating for the lung cancer community since 2012. Making our representatives in DC aware of the significant funding inequity of Lung Cancer research. Ready to enjoy retired life in Northern California and the Algarve. Transforming your health is more fun with friends! Join Chef AJ's Exclusive Plant-Based Community. Become part of the inner circle and start simplifying plant-based living - with easy recipes and expert health guidance. Find out more by visiting: https://community.chefaj.com/

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available from July 1 that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities. - 肺がんは、オーストラリアで5番目に多く診断されているがんですが、発見が遅れることが多く、がんによる死亡原因の中で最も多くなっています。こうした中、7月1日から新たな肺がんの検診プログラムが始まりました。

On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fellowship Program at Johns Hopkins University.

Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here.

Featuring perspectives from Prof Marina Chiara Garassino, Dr John V Heymach, Prof Solange Peters and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters (2:07) Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino (26:30) Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands (50:19) Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach (1:12:36) CME information and select publications

Jesus Delivered Us (5) (audio) David Eells – 7/16/25 Saints, I want to point out to you that if you want deliverance from any demon, do not put the responsibility for the sin upon the demon. What did Peter say to Ananias and Sapphira? (Act.5:3) … Ananias, why hath Satan filled thy heart to lie to the Holy Spirit …? Was Peter blaming the lying spirit, or was he blaming Ananias? Some people have demons they inherited through the bloodline (Exodus 20:5, 34:7; Numbers 14:18; Deuteronomy 5:9), but we are born in sin. Psa 51:5  Behold, I was brought forth in iniquity; And in sin did my mother conceive me.  If you have a demon because of what you have done, guess what? You are still guilty. The Bible does not let you get off without being guilty. So the solution is 1Jn 1:9  If we confess our sins (not the demons sins), he is faithful and righteous to forgive us our sins, and to cleanse us from all unrighteousness.  (Pro.26:2) As the sparrow in her wandering, as the swallow in her flying, So the curse that is causeless alighteth not. See, there are people who just run from ministry to ministry looking for somebody to give them deliverance, but they will not first repent. They think all they need is deliverance, but God says they need to repent, because you can get delivered of anything and everything if you repent and believe. So there may be things you have never been delivered of yet, but God's plan is to deliver you from lusts of the flesh and demon spirits that take advantage of them. Let's look at some Old Testament types and shadows about delivering the Promised Land that show us the way God leads us from the time we come to know Him. This “house,” your body, is supposed to be ruled over by the spiritual man, and for that to happen, the carnal man who lives in your house has to be driven out and killed. This is a type of taking the Promised Land. Those Israelites represent the spiritual man, and those Canaanites represent the carnal man. God told them the Canaanites had to be driven out and killed, and the Israelites had to live in their houses. God said in (Deu.7:2) And when the Lord thy God shall deliver them up before thee, and thou shalt smite them; then thou shalt utterly destroy them: thou shalt make no covenant with them, nor show mercy unto them. And He also commanded, (Exo.23:33) They shall not dwell in thy land, lest they make thee sin against me; for if thou serve their gods (demons), it will surely be a snare unto thee. You see, if you leave one of the lusts of the flesh in your land, it is going to cause you to sin, so don't leave them and don't bow down to their gods. (Exo.23:20) Behold, I send an angel before thee, to keep thee by the way, and to bring thee into the place which I have prepared. By the way, you have an angel, too, as the Bible says in (Heb.1:14) Are they not all ministering spirits, sent forth to do service for the sake of them that shall inherit salvation? These spirits are with us to bring us into this salvation that Jesus provided. Exodus 23 is an exact parallel. (Exo.23:21) Take ye heed before him, and hearken unto his voice; provoke him not; for he will not pardon your transgression: for my name is in him. God's Name, which is His Nature, Character, and Authority, is in those angels. His Nature is so strong in them that they are perfect prophets for the Lord, and when an angel speaks to you, he speaks to you with the Voice of God. In the Book of Acts, Stephen said it was an angel who spoke out of the burning bush to Moses. (Acts 7:30) And when forty years were fulfilled, an angel appeared to him in the wilderness of Mount Sinai, in a flame of fire in a bush. An angel spoke to Moses with the Voice of God. (Exo.23:22) But if thou shalt indeed hearken unto his voice, and do all that I speak; (We see the Lord is speaking, but it is the angel's voice.) then I will be an enemy unto thine enemies. If you obey His Voice, He will be an enemy to your enemies. If you do not obey His Voice, He is not going to be an enemy to your enemies. You may run around everywhere looking for your deliverance from flesh and spirit, but you will fail when you are not obeying His Voice. (Exo.23:23) For mine angel shall go before thee, and bring thee in unto the Amorite, and the Hittite, and the Perizzite, and the Canaanite, the Hivite, and the Jebusite: and I will cut them off. These are the original inhabitants of the land. They represent the lusts of the flesh that live in our Promised Land right here, and the Lord is going to lead us to sanctification from every one of these lusts. Each group of these original inhabitants represents the old man ruled over by demon gods with matching specialties and each of their names has a meaning. “Canaanite” means “to bend the knee, to humiliate, to subdue.” “Amorite” means “prominent,” and of course, one of the evils of the flesh is pride. “Hittite” means “terror, fear.” There are many different kinds of demons of fear, and God wants to deliver us from all kinds of fear. Your flesh fears many things; you could have a fear of rejection or a fear of heights and so on. “Perizzite” means “to separate.” Think about it; religions separate from religions and nations separate from nations. Factions separate. When religions separate from each other, it's “sectarianism,” which Paul listed among works of the flesh. (Gal.5:19) Now the works of the flesh are manifest, which are [these:] fornication, uncleanness, lasciviousness, (20) idolatry, sorcery, enmities, strife, jealousies, wraths, factions, divisions, parties, (21) envyings, drunkenness, revellings, and such like… Paul called them “lusts of the flesh”; we call them “denominations.” And countries naturally have a bias toward the people who live in their nation, but we are not supposed to be divided from Christians anywhere in the world. We are a holy nation (1 Peter 2:9). We are “one man in Christ Jesus.” (Gal.3:28) There can be neither Jew nor Greek, there can be neither bond nor free, there can be no male and female; for ye all are one [man] in Christ Jesus. That means a Christian over in Russia is my brother; I am not going to fight for America to kill a Christian over in Russia, or anywhere else. It is wrong! This is worldly thinking and we need to understand that Jesus said, (Joh.18:36) My kingdom is not of this world… We are one holy nation, so no matter where on earth we are living, we are supposed to be a part of (Heb.12:22) … the city of the living God, the heavenly Jerusalem. “Jebus” was the old name for Jerusalem, and it's interesting that “Jebusite” means “trodden down.” The Bible says that Jerusalem will be “trodden down.” (Luk.21:24) Jerusalem will be trodden down of the Gentiles, until the times of the Gentiles be fulfilled. Revelation 11 talks about the outer court being trodden down. (Rev.11:2) And the court which is without the temple leave without, and measure it not; for it hath been given unto the nations: and the holy city shall they tread under foot forty and two months. Jesus told us in (Mat.5:13) Ye are the salt of the earth: but if the salt have lost its savor, wherewith shall it be salted? it is thenceforth good for nothing, but to be cast out and trodden under foot of men. It's the old Jerusalem, not the New Jerusalem, who is going to be trodden down. Old, unregenerate Jerusalem was Jebus. They were trodden down that New Jerusalem could take their place. Going on in (Exo.23:24) Thou shalt not bow down to their gods, nor serve them, nor do after their works… Notice two things in this verse: “their gods” and “their works.” If you live after the lusts of your flesh, that is your works, and if you “bow down to their gods,” then you're being ruled by demons. It says in (1Co.10:20) But [I say,] that the things which the Gentiles sacrifice, they sacrifice to demons, and not to God: and I would not that ye should have communion with demons. You see, every one of the lusts of the flesh has a demon spirit that rules over it. Jesus Christ sowed a Seed in us to bring forth the fruit of the Spirit, but the demons have sown other seeds in mankind. They have sown seeds of anger, seeds of lust, and seeds of rebellion, and the flesh has been bringing forth what is called the “lusts” of the flesh, which is another way of saying “fruit” of the flesh (Galatians 5:19-21; 2 Peter 2:10-19). Demons are the ones who sowed the seeds that have brought this forth. They are the gods of the lusts of the flesh and God commanded us to kill them and not to serve their gods. (Exo.23:33) They shall not dwell in thy land, lest they make thee sin against me; for if thou serve their gods, it will surely be a snare unto thee. He is talking about marching through this Promised Land, and putting to death, one by one, the lusts of the flesh. And He is talking about not submitting, not bowing down, to their gods. If you are throwing out their “flesh,” you are throwing out the demon gods' power. If you simply throw out the demon gods and hold on to the flesh, they will be back. We are this Promised Land that has to be sanctified. The word “sanctified” means “separated from sin, separated from the curse, and separated unto God.” As God led the Israelites through their Promised Land and they put to death the original inhabitants with a physical sword, so we are led of the Holy Spirit through our promised land to put to death the lusts of the flesh with the “sword” of the Spirit, which is the Word of God. (Heb.4:12) For the word of God is living, and active, and sharper than any two-edged sword, and piercing even to the dividing of soul and spirit, of both joints and marrow, and quick to discern the thoughts and intents of the heart. And it is two-edged because one edge is for you. We are commanded to Put to death therefore your members which are upon the earth: fornication, uncleanness, passion, evil desire, and covetousness, which is idolatry. (Col.3:5) The devil fears you if you know your authority and you are walking with God. Now, what about casting out demons from the lost? Are we authorized to do that? One time, I had been asking God about casting demons out of my mother. She had come to live with us in our house, but she didn't know the Lord. Most people do not know you need permission from God to cast demons out of a lost person, but it's biblical. (Luk.11:24) The unclean spirit when he is gone out of the man, passeth through waterless places, seeking rest, and finding none, he saith, I will turn back unto my house whence I came out. (25) And when he is come, he findeth it swept and garnished. (26) Then goeth he, and taketh [to him] seven other spirits more evil than himself; and they enter in and dwell there: and the last state of that man becometh worse than the first. You see, the lost person will get them seven times worse if you cast the demons out without the person turning to God. There are “loopholes” in the Bible, and so I asked God for permission to cast the demons out of my mother on the basis that my house is not cursed, but she was in my house and bringing me under a curse. I asked, “God, I am not under the curse. Can I cast the demons out of her because she is bringing a curse upon me?” God gave my daughter Jennifer a dream that night. She saw my mother's house in the middle of my house, except it was three stories tall, sticking out of the top of my house. Out of the second floor, representing the soul, there was a plank leading out to the street. Five chickens, representing unclean spirits, were on it and they were walking the plank to the street. Well, I knew exactly what the Lord was saying. That night, Mama, full of demons, came to our bedroom door and her demons threatened us, “I am going to keep you awake all night!” I said, “Oh no you're not!” My wife and I jumped up and went into her room, and as we stood there, God gave us five spirits to cast out. We didn't even wait to see them come out. We just commanded, “Come out in the Name of Jesus!” as fast as we could name them. Then we marched out, went back to bed, and slept peacefully all night. The next day, we noticed that it was awfully quiet in that room. Not knowing what was going on, we opened the door and peeked in to see that her room was a total mess. And there was my mother, crawling out from under the bed! She had been wrestling in there with something all night long, but when she came out, she was humble, meek, and submissive. I never knew my mother to be that kind of person. She had been demon-possessed all of her life; she had been taking medication all of her life to keep those demons in subjection. Her “religion” had kept her from turning to God when she had the opportunity, but as long as she was in my house, we had peace. When the demons started drifting back, the Lord took her out of my house. As she was dying she returned to peace. There are several reasons why God will give deliverance to the lost, and we should read the Bible like a lawyer because God put loopholes in there so you can step through them sometimes. Another great loophole that the Lord showed me is that if somebody is a blessing to you, you can be a blessing to them. It does not matter if they are lost. We have the example of when Paul was shipwrecked on Melita and the natives of the island came to the rescue. They were very kind to Paul and the others who were cold and wet. The natives dried their clothes and got them out of the rain (Acts 28:1-2). (Act.28:7) Now in the neighborhood of that place were lands belonging to the chief man of the island, named Publius, who received us, and entertained us three days courteously. (8) And it was so, that the father of Publius lay sick of fever and dysentery: unto whom Paul entered in, and prayed, and laying his hands on him healed him. He never preached the Gospel to him; he just healed him. Then they brought all the sick people on the island to Paul. He prayed for them and God healed them. (Act.28:9) And when this was done, the rest also that had diseases in the island came, and were cured. You do not see this elsewhere in the Bible because “healing is the children's bread” (Matthew 15:26), so I asked, “Why is this, Lord?” The Lord answered, “They were kind to them.” God will let you pray for somebody and heal them because they were good to you. He said, (Gen.12:3) And I will bless them that bless thee, and him that curseth thee will I curse: and in thee shall all the families of the earth be blessed. This is talking about us; we are the “Israelites.” There's one loophole, too, that's the mercy of God. The demoniac described in the Gospels was so far gone that you could not expect the man to have faith or make a rational decision, and Jesus cast the demons out of him, knowing what kind of decision he was going to make afterward (Matthew 8:28-34; Mark 5:1-20; Luke 8:26-39). Sometimes God does this, but He does not have to do it. Now let me share with you the following testimony: Delivered from Scoliosis by D. M. My brother-in-law once bought me a book by Henry W. Wright entitled “A More Excellent Way: A Teaching on the Spiritual Roots of Disease.” I found the book to be fascinating and, as the British say, “spot-on” in many ways. (There is definitely a connection between a sin and its curse. Quite often, a sickness can identify the sin.) I have a good friend named “A” whom I've known since I was saved. We have conversed via phone for years, since we live in different states. A couple of years ago, he mentioned that he'd had scoliosis since childhood. I didn't say anything to him, but I went to Henry Wright's book and looked up what he had to say about scoliosis. I kept this to myself because I didn't feel right bringing it up to “A.” I knew the time would come as the Lord gave me freedom to do so. Today, I received an email from “A” asking me to pray for him for deliverance from a particular sin. He did not go into detail but gave me a hint. I replied that I would pray for him in a moment. But first I wanted to know when his scoliosis had begun, and if, in fact, it had begun about the time of his traumatic incident. He replied back that it did begin right afterwards. I decided to give him a call. We talked. He made a full confession of the incident. I quoted (Jas.5:16) Confess therefore your sins one to another, and pray one for another, that ye may be healed. The supplication of a righteous man availeth much in its working. And I told him that there was now nothing in the way of his deliverance. I prayed over the phone with him in agreement. Glory be to God, a hundred-pound weight came off my friend and he was delivered from the evil spirit of scoliosis and was healed! Awesome! Praise the Lord! Saints, we need to be led of the Spirit and wait for the Lord's leading so He can open the way for us to minister to others. Here's another testimony I'd like to share with you. Delivered from Lung Cancer by Linda L. (This lady was healed of a spirit of cancer when I for the brethren in our meeting rebuked it, although she was not present at that meeting. She related to us how, later that same night, what looked like smoke came out of her nose and she knew she was healed. Please note that she had faith to be healed.) My doctor's office called to tell me I had an inconsistency on my chest x-ray. I needed to go to the hospital for another x-ray. The second x-ray was not any better than the first. A CT scan was ordered. The suspicious spot was a ten-centimeter (approximately two inches) sized nodule in the upper right lobe. That night after numerous internet searches, I was devastated to learn that most nodules are malignant. My father had died of lung cancer in 1998. I am very familiar with the disease. At this point I started to do a lot of praying. Even though I knew Jesus heard my prayer, I did not have peace yet. My doctor sent me to a pulmonary specialist. The first thing Dr. Wagner told me was that I was not to worry. The surgeon would remove my lobe. I would not have to undergo chemotherapy or radiation. He started to ask questions about health, lifestyle, etc., and we talked more. He decided to wait and repeat the CT scan in two months. At this point, I told Dr. Wagner that God would heal me. He did not say anything, but I am sure he thought I was deluded. I am a very reserved person. I usually do not share information of this nature with many people. However, the Holy Spirit prompted me to tell Dr. Wagner how Jesus would heal my lung. When I saw Bob, a UBM elder, I told him my predicament. And as we talked, I asked his group to pray for my healing. Jesus would heal me. This was a Tuesday. I did not see Bob during the week, but I KNOW his prayer group prayed for me. A peace beyond all understanding came over me Saturday night. During the middle of the night, I saw an evil spirit leave my lungs! I KNEW I was healed. The next month arrived. It was time to repeat the CT scan. The doctor at the Imaging Center observed the entire scan. He reported the nodule was starting to calcify. In his opinion the nodule was now benign. Tears and praise flowed, as Jesus had healed me. Dr. Wagner told me I was one lucky lady. I reminded him that Jesus would heal me. The doctor did not acknowledge anything yet, but he knows that this healing from a deadly lung nodule was a miracle. Jesus hears our prayers and heals those who ask and have faith. He knows our pain. He honors His commitment to us when we believe Him and the works of His hands. Amen! That's so true! Praise You, Lord! Let's look at this parable in the Old Testament, how God delivers us. The Lord says in (Exo.23:27) I will send my terror before thee, and will discomfit all the people to whom thou shalt come, and I will make all thine enemies turn their backs unto thee. (28) And I will send the hornet before thee, which shall drive out the Hivite, the Canaanite, and the Hittite, from before thee. You know, it's easy to win a battle when your enemy is afraid, and making your enemy fearful is a proven strategy of warfare. There have been great battles won by very small armies against very large armies, all because fear was in the larger army. This happened to Israel in the 1967 Arab-Israeli War when Arabs attacked them from all sides. Israel won overwhelming victories against all odds because God put fear in the hearts of their enemies. It's a quick battle when the enemy is fearful. Only God is able to do this! He did this in many places in the Scriptures, giving the Israelites tremendous victories. We have a good example where they sent spies into the Promised Land to understand their enemies' thinking. (Jos.2:1) And Joshua the son of Nun sent out of Shittim two men as spies secretly, saying, Go, view the land, and Jericho. And they went and came into the house of a harlot whose name was Rahab, and lay there… (8) And before they were laid down, she came up unto them upon the roof; (9) and she said unto the men, I know that the Lord hath given you the land, and that the fear of you is fallen upon us, and that all the inhabitants of the land melt away before you. (10) For we have heard how the Lord dried up the water of the Red Sea before you, when ye came out of Egypt… Going through the Red Sea was their salvation experience. Guess who knows immediately about our salvation experience? Demon spirits. They know who we are, but the problem is not that they know; the problem is, do we know? This is why we need to study the Scriptures; it's important that we find out who we are. Unless we know who we are, demon spirits can, and do, take advantage of us, but when you know who you are according to Scripture, the demons are fearful. In the dream that the Lord gave my daughter, the Lord had a sense of humor because He pictured the five demons as five chickens. Our enemies know that they cannot keep us from taking our land. (Jos.2:10) For we have heard how the Lord dried up the water of the Red Sea before you, when ye came out of Egypt; and what ye did unto the two kings of the Amorites, that were beyond the Jordan, unto Sihon and to Og, whom ye utterly destroyed. (11) And as soon as we had heard it, our hearts did melt, neither did there remain any more spirit in any man, because of you: for the Lord your God, he is God in heaven above, and on earth beneath. All of these verses are types and shadows of our enemies being fearful of us. (Jos.1:5) There shall not any man be able to stand before thee all the days of thy life: as I was with Moses, so I will be with thee; I will not fail thee, nor forsake thee. (6) Be strong and of good courage; for thou shalt cause this people to inherit the land which I sware unto their fathers to give them. (7) Only be strong and very courageous, to observe to do according to all the law, which Moses my servant commanded thee: turn not from it to the right hand or to the left, that thou mayest have good success whithersoever thou goest. (8) This book of the law shall not depart out of thy mouth, but thou shalt meditate thereon day and night, that thou mayest observe to do according to all that is written therein: for then thou shalt make thy way prosperous, and then thou shalt have good success. Spiritually speaking, the Lord is talking about taking this “land” in which we live, taking this land of the soul, which is our mind, our will, and our emotions. God says, (Exo.23:29) I will not drive them out from before thee in one year, lest the land become desolate, and the beasts of the field multiply against thee. From this example, we see that it is not God's plan to purify us instantly, but almost every Christian religion teaches some form of “instantaneous sanctification.” They say all you need to do is get saved and you're sanctified. A number of them also believe that you're automatically filled with the Holy Spirit. In other words, there's a line you just step over and that's all there is to it; then you can sit down and take it easy. No, we can never sit down and take it easy because we have a land to conquer. God goes on to say, (Exo.23:30) By little and little I will drive them out from before thee, until thou be increased, and inherit the land. “Little by little” is God's plan. People who have their “instantaneous sanctification” theology do not understand that sanctification is when you are delivered of all the lusts of the flesh to the point where you're not even going to be tempted anymore. The ultimate end of sanctification is when the flesh is dead. We can all think of things in our lives from which God delivered us. They do not even tempt us anymore because that flesh is dead, but God wants to continue that process until He goes through all of our “Promised Land.” God wants to lead you to your enemy, give you the Sword of the Spirit (Ephesians 6:17), and put the fear of God in you (Psalms 111:10; Proverbs 1:7; etc.) He wants to give you understanding to know that you have victory through the Gospel and through the Blood of Jesus. So the Lord said, (Exo.23:22) But if thou shalt indeed hearken unto his voice, and do all that I speak; then I will be an enemy unto thine enemies, and an adversary unto thine adversaries. But He also says, (Exo.23:29) I will not drive them out from before thee in one year… and (Exo.23:30) By little and little I will drive them out from before thee… Well, the people of Israel did not “hearken unto his voice” to do all that the Lord spoke. We read in (Jdg.21:25) In those days there was no king in Israel: every man did that which was right in his own eyes. (Jdg.2:20) And the anger of The Lord was kindled against Israel; and he said, Because this nation have transgressed my covenant which I commanded their fathers, and have not hearkened unto my voice; (21) I also will not henceforth drive out any from before them of the nations that Joshua left when he died; (22) that by them I may prove Israel, whether they will keep the way of The Lord to walk therein, as their fathers did keep it, or not. (23) So the Lord left those nations, without driving them out hastily; neither delivered he them into the hand of Joshua. If you break God's Covenant, He is not going to do a quick work of delivering your enemies into your hand. The Blood is our weapon to cleanse us from all unrighteousness. The New Testament says, (1Jn.1:7) But if we walk in the light, as he is in the light, we have fellowship one with another, and the blood of Jesus his Son cleanseth us from all sin. (8) If we say that we have no sin, we deceive ourselves, and the truth is not in us. (9) If we confess our sins, he is faithful and righteous to forgive us our sins, and to cleanse us from all unrighteousness. The Blood cleanses as we walk in the light and as we obey what we know to obey. We cannot do anything about what we do not know, but as we do what we know to obey, the Blood cleanses. These “lusts of the flesh” and their “gods,” which have the same names, have to be driven out. Every lust of the flesh has a “god.” It's the demon spirit, having the same name, that rules over that particular lust. God said He is not going to be in a hurry to drive out your enemies if you are going to rebel. The Bible says in (Luk.12:48) And to whomsoever much is given, of him shall much be required. If you do something with what God gives you, He will give you more, but if you do not do something with what He has already given you, He is not going to give you anymore. You're going to stop right in your tracks because God is a merciful God. Otherwise, you would be condemned for not doing even more, and so when you stop doing something with your Sword against your enemy, God is going to stop. God does not flood us with knowledge of our every evil. He leads us to each individual evil, step-by-step, and He expects us, at that point and time, to do something about it. If He were to just flood our minds with the knowledge of all of the evil in us, we would be overwhelmed and probably lose faith. And if we didn't do something with all that knowledge, we would be condemned. When you have a lot of knowledge, Scripture warns us, (Jas.4:17) To him therefore that knoweth to do good, and doeth it not, to him it is sin. When you have a lot of knowledge, yet do nothing, you have a lot of sin. God brings these enemies up, one at a time, in front of our face. This usually occurs through temptation, through something happening around us. When He brings these enemies up in front of our face, we have an opportunity to use the Sword to come against that enemy. We can reject that lust of the flesh and command it to go in the Name of Jesus. If there is any demon spirit in our flesh, or if there is any demon spirit using that lust of the flesh to exercise authority in our soul, we can come against it, and we can win right there. We do not have to live with these demons all of our lives or go searching for some deliverance ministry, because we have authority over demon spirits and the flesh (Matthew 28:18-19; Luke 10:19; etc.) We're told, (Rom.6:11) Even so reckon ye also yourselves to be dead unto sin, but alive unto God in Christ Jesus. This is what we have to believe. We are dead unto sin, but alive unto God. We have total authority over the Hittites, the Girgashites, the Hivites, the Canaanites, and so forth. We have total authority over them and their gods. Every one of us can learn to exercise our Sword, the Word, against the lusts of the flesh and those spirits. We don't have to live with them anymore, but God is only going to continue this process as long as we cooperate. We are here to conquer our Promised Land, and there's no time for us to rest in the flesh. Our rest is in the Spirit. Our rest is in the promises of God. We can safely rest in His Word. The quicker we submit to him and resist the devil, the quicker we win. It says in (Psa.81:10) I am the Lord thy God, Who brought thee up out of the land of Egypt (He delivered you from the power of the old man at the Red Sea baptism.): Open thy mouth wide, and I will fill it. That is, “Say what I say,” speak as an oracle of God (1 Peter 4:11). And (11) But my people hearkened not to my voice; And Israel would none of me. (12) So I let them go after the stubbornness of their heart, That they might walk in their own counsels. (13) Oh that my people would hearken unto me, That Israel would walk in my ways! (14) I would soon subdue their enemies (If we obey and fight the enemy, we will “soon” win.), And turn my hand against their adversaries. And they will be conquered. (15) The haters of the Lord should submit themselves unto him: But their time should endure for ever. (16) He would feed them also with the finest of the wheat; And with honey out of the rock would I satisfy thee. It's our obedience that brings the blessings. Remember, we are to be vigilant when we are in a trial because it's our opportunity to come against that particular enemy in our Promised Land and win. God brought us to this enemy for us to conquer it, and to do it now. This is why we are here. He has given us total authority over that enemy. There is no such thing as a “giant” in our Promised Land since even the least of us has total authority over the mightiest demon that comes into contact with us. God is walking with you. You need to realize that He wants your enemies to be conquered here and now, day by day, little by little. (Psa.81:11) But my people hearkened not to my voice; And Israel would none of me. (12) So I let them go after the stubbornness of their heart, That they might walk in their own counsels. You see, if you're resting in the flesh, rather than resting in the Spirit, then you are not doing anything. We are here to redeem the time and to win a battle. (Eph.5:15) Look therefore carefully how ye walk, not as unwise, but as wise; (16) redeeming the time, because the days are evil. (17) Wherefore be ye not foolish, but understand what the will of the Lord is. What is His Will for us if we walk in His ways? (Psa.81:13) Oh that my people would hearken unto me, That Israel would walk in my ways! (14) I would soon subdue their enemies, And turn my hand against their adversaries. You may say, “Well, David, that's exactly my problem, walking in His ways,” but there is always a step you can take, however small it may be. If He makes us responsible to walk in His ways, then we can walk in the light. (1Jn.1:7) But if we walk in the light, as he is in the light, we have fellowship one with another, and the blood of Jesus his Son cleanseth us from all sin. We can take those steps. (Pro.4:18) But the path of the righteous is as the dawning light, That shineth more and more unto the perfect day. You can take one step at a time, and God will be with you each step.

Lung cancer has a high chance of relapse, so how do we get out of ahead of it? Nancy Guo, SUNY Empire Innovation Professor in the school of computing at Binghamton University, discusses technology that helps us do so. Nancy Guo is one of the newest additions to the Binghamton University School of Computing as […]

Over 80% of patients referred to University Hospital Limerick for an appointment at a lung cancer clinic last year were seen within 10 days. Although this rate of 82% sounds encouraging, it was the lowest in the country when compared to Rapid Access Clinics in Dublin, Cork, Waterford and Galway and is well below the national target of 95%. According to the Irish Cancer Society, UHL's lowest level of compliance throughout the year in this regard was 60%. For more on this Alan Morrissey was joined by, Antoinette Baker Bashua, a HSE Regional Health Forum West member, and is also a Breast Cancer Survivor.

In episode 90 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Brandon Leum, Founder of @buildingarefuge. Tune in as Brandon shares the organization's mission to bring hope and encouragement to men through meetings, events, and the BAR Podcast. You can connect with Building a Refuge at buildingarefuge.org.

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of deaths because it is often diagnosed too late. A new screening program has become available that hopes to detect cases much earlier for those at the highest risk - which includes Indigenous Australians and some migrant communities.

In this episode, Dr. Paul Wheatley-Price chats with Claire Hopkins, Registered Dietician at the Princess Margaret Cancer Center, about all things nutrition and maintaining heathy eating habits for lung cancer patients. What exactly is the role of a dietician vs nutritionist, is sugar really bad for cancer, tips to maintain a healthy appetite, reasons behind weight loss during treatment, and the best supplements or meal alternatives.

Humans have long been exposed to three main types of smoke: from early domestic fires, modern wildfires, and more recently, tobacco and fossil fuel pollution. All release tiny particles from partly burned plants, containing harmful chemicals like nitrogen oxides and carcinogens. These particles raise risks for lung cancer, dementia, and even childhood obesity. Studies show that air pollution can disrupt brain chemistry, increase Alzheimer's-related proteins, and activate stress-related genes (NFkB, Nrf2). A new drug (GSM-15606) shows promise in reducing brain damage from pollution in mice. People with the ApoE4 gene may be more vulnerable, while the ApoE3 gene, possibly evolved 200,000 years ago, may offer some protection. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40700]

Humans have long been exposed to three main types of smoke: from early domestic fires, modern wildfires, and more recently, tobacco and fossil fuel pollution. All release tiny particles from partly burned plants, containing harmful chemicals like nitrogen oxides and carcinogens. These particles raise risks for lung cancer, dementia, and even childhood obesity. Studies show that air pollution can disrupt brain chemistry, increase Alzheimer's-related proteins, and activate stress-related genes (NFkB, Nrf2). A new drug (GSM-15606) shows promise in reducing brain damage from pollution in mice. People with the ApoE4 gene may be more vulnerable, while the ApoE3 gene, possibly evolved 200,000 years ago, may offer some protection. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [Humanities] [Science] [Show ID: 40700]

“Just remember that these patients, these are human beings who had lung cancer. It's a scary disease. And we don't want to just say, ‘Oh, well, that's a horrible disease. They probably won't do well.' These patients are living longer. Our treatments are better. And so no matter who they are, they have every chance of surviving long term for this,” ONS member Beth Sandy, MSN, CRNP, thoracic medical oncology nurse practitioner at the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about lung cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 27, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to lung cancer survivorship. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities ONS Voice articles: Nursing Considerations for Lung Cancer Survivorship Care Nurse-Led Survivorship Programs: Expert Advice to Help You Build Your Institution's Resources Oncology Nursing Forum articles: Empowering Lung Cancer Survivors in Post-Treatment Survivorship Care Using Participatory Action Research A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review ONS Survivorship Care Plan Huddle Card ONS Survivorship Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For patients with stage I disease, they have a pretty good chance of getting to that five-year mark, somewhere probably in the 70%–80% range, depending on if you're stage IA or IB. Then it starts to drop obviously if you go up stages with patients.” TS 6:36 “Our radiation oncologists … and the dosimetrists in radiation oncology do a great job trying to line those beams up to minimize toxicity to those other vital organs. But we just can't always do that. You may see long-term fibrotic changes within the lungs. You could see cardiac damage over time. You can see esophagitis or [gastrointestinal] toxicity, particularly in the esophagus over time, post-radiation. And just the fact of having disease or cancer in the lungs, you can have breathing problems and pulmonary issues long term.” TS 10:37 “Part of survivorship in lung cancer is smoking and smoking cessation. I know it can be hard for people to quit, even people who had curative-intent treatment for their lung cancer—and so keeping up with smoking cessation. And that can be hard again if you don't have access to a smoking cessation specialty or if you live with other people who smoke and don't have really access to programs to help you quit and help you stay quitting.” TS 17:26 “I should talk about autoimmune diseases as part of immunotherapy. We give immunotherapy now in the curative setting preoperatively, postoperatively, post-chemoradiation, so they may get a year or so of immunotherapy. They may develop some sort of autoimmune toxicity from that. Usually that will go away once we stop the immunotherapy. But I've seen some things persist over time. That can go anywhere from like mild eczema that came about to things like more serious, like maybe lupus or scleroderma that may have developed as part of your immunotherapy. And we may stop the immunotherapy, but that may linger on.” TS 25:02  

Since that first interview, Richard has faced multiple cancer recurrences—including brain tumors and cancer in his remaining lung—and continues to rely on cannabis oil as a central part of his healing. In this episode, he talks candidly about living with cancer, navigating the challenges of legalization, dealing with skeptical doctors, and staying grounded with family, humour, and positivity.00:37 – Introduction to Richard Lusk and his original interview from 201601:17 – How Richard first discovered his lung cancer02:45 – Starting cannabis oil and watching tumors shrink03:45 – Leaving Washington to care for his mother in Kansas—cannabis access cut off04:30 – Cancer returns and spreads to his brain05:38 – Returning to Washington for treatment and cannabis access06:10 – Telling his oncologist about cannabis oil07:02 – Doctors say it's incurable—Richard disagrees07:53 – How he takes a gram of cannabis oil each day08:54 – Symptoms that led to brain tumor discovery09:39 – Years in construction and staying physically resilient10:28 – Emotional vs. physical challenges of illness11:40 – Thoughts on legal cannabis access across the U.S.12:57 – Adrenal gland cancer and additional surgeries13:44 – Belief in cannabis over conventional treatments16:07 – The role of cannabis in surviving cancer17:40 – Advice for people newly diagnosed with cancer18:41 – Staying positive and the importance of family20:52 – Choosing your own path despite family opposition21:12 – Current restrictions and chemo side effects22:48 – Gratitude for life and simple pleasures23:26 – A brain surgeon's 6.5 rating and Richard's humour24:38 – Final thoughts, hope for change, and sharing his story Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Early detection of lung cancer can save lives. In this essential episode, two-time survivor and LCFA co-founder David Sturges shares how screening helped him beat lung cancer—twice. Joined by Dr. Denise Aberle and LCFA-funded researcher Dr. Kellie Smith, this episode dives into why lung cancer is often diagnosed late, what new screening methods can do to change that, and what the future of early treatment might look like. Guests David Sturges, Lung Cancer Survivor & LCFA Co-founder  Dr. Denise Aberle, Thoracic Radiologist, UCLA Medical Center Kellie Smith, Ph.D., Assistant Professor of Oncology, Johns Hopkins University & LCFA Early Career Researcher Show Notes | Transcript  

Drs. Scott and Liu discuss the safety of treatments for HER2-mutant lung cancer, including key toxicities, management strategies, and how prior therapies might affect treatment decisions.

Imagine being told you only have 12 months to live. What would you do with your time? Today on Your Money, Your Wealth podcast number 532, Big Al Clopine, CPA and Executive Producer Andi Last are thrilled to welcome Jonathan Clements back for his fourth appearance. For thirty years, Jonathan has been known for his personal finance writing: in his column “Getting Going,” which appeared in the Wall Street Journal over 1,000 times starting in 1994, on his website HumbleDollar.com, and in his many acclaimed books. About a year ago, Jonathan Clements was diagnosed with a rare form of lung cancer and was told he had about a year to live. Today we're celebrating the fact that he is still here with us, and we're inspired by his decision to use his precious time to launch The Jonathan Clements Getting Going on Savings Initiative. Watch or listen to find out how you can get a free Kindle copy of Jonathan's new book, and how you can help Jonathan pay it forward for the next generation. Free financial resources & episode transcript: https://bit.ly/ymyw-532 The first 100 people to email us will receive a free Kindle copy of The Best of Jonathan Clements: Classic Columns on Money and Life WATCH Retirement Sabotage! 12 Post-Retirement Money Mistakes to Avoid on YMYW TV ASK Joe & Big Al for your Retirement Spitball Analysis SCHEDULE your Free Financial Assessment SUBSCRIBE to YMYW on YouTube DOWNLOAD more free guides READ financial blogs WATCH educational videos SUBSCRIBE to the YMYW Newsletter Timestamps:  00:00 - Intro: This Week on the YMYW Podcast 02:53 - Jonathan Clements' Getting Going on Savings Initiative 05:23 - $1,000 Roth IRA Contributions and Personal Finance Education for Young Adults 07:55 - Exponential Growth: The Sooner You Save, The Better 09:44 - Research Study Will Measure Impact on Young Savers 11:56 - Financial Education is Important 14:05 - The John C. Bogle Center for Financial Literacy 14:38 - The First 100 People to Email Us Receive a Free Copy of The Best of Jonathan Clements: Classic Columns on Money and Life 15:45 - How Does a Healthy 62-Year-Old Non-Smoker End Up Living With Stage IV Lung Cancer? The EGFR Exon 20 Insertion Mutation 18:52 - HumbleDollar.com, The Jonathan Clements Getting Going on Savings Initiative, and The Best of Jonathan Clements Book

In this deeply inspiring follow-up conversation, Jay Jay shares the life-changing role that cannabis has played in her journey, including her unexpected recovery from severe pain, a recurrence of brain tumors, and even a broken vertebrae from a seizure. She also speaks candidly about addiction, emotional healing, diet changes, and the power of education. Now working as Executive Director of EduCanNation, Jay Jay is paying it forward by helping others navigate their healing paths with cannabis and community.00:37 – Introduction: Jay Jay's return, 5+ years post-terminal diagnosis01:22 – Jay Jay's gratitude for the podcast and tribute to Corrie Yelland02:30 – Physical vs. emotional healing, addiction, and cannabis support03:44 – 10 months of undiagnosed pain before Jay Jay insisted it was cancer05:04 – Emotional toll of her prognosis and the loss of her mother06:11 – A fight for her life begins—rejection of the medical “death sentence”07:05 – No chemo, no radiation offered—turning to cannabis07:27 – The moment of clarity: watching Weed the People07:59 – Early cannabis oil experience: rookie mistake, fast pain relief09:20 – Daily dose now: 1.5 to 2 grams; feeling better than ever10:00 – A gene mutation leads to targeted therapy11:29 – Brain metastases return in 2023—11 tumors, then 8 more12:37 – Seizure leads to spinal fracture; cannabis helps her heal13:56 – Headaches and midline shift caused by brain tumors15:22 – Ian shares cannabis success stories for brain cancer15:58 – Jay Jay on life transformation—body, mind, and soul16:18 – Gaining new perspective after a “death sentence”17:07 – Her advice to those newly diagnosed: don't lose hope18:38 – The birth of EduCanNation and its founding story20:16 – Jay Jay's cannabis education journey and certifications21:11 – Cannabis skepticism vs. chemo acceptance—societal brainwashing22:39 – Helping others: a story about supporting her father-in-law24:25 – Emotional resilience and growth24:41 – Diet transformation—from vegetarian to carnivore27:07 – Honouring individual needs: no one-size-fits-all diet28:03 – Feeling healthier than ever despite diagnosis28:10 – How to contact Jay Jay and connect with EduCanNation Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover